Verastem Inc (NASDAQ:VSTM) – Analysts at Roth Capital lifted their FY2016 earnings per share (EPS) estimates for Verastem in a note issued to investors on Tuesday. Roth Capital analyst J. Pantginis now expects that the brokerage will earn ($0.89) per share for the year, up from their prior forecast of ($0.94). Roth Capital also issued estimates for Verastem’s Q4 2016 earnings at ($0.22) EPS, FY2017 earnings at ($0.92) EPS, FY2018 earnings at ($0.90) EPS and FY2019 earnings at ($1.08) EPS.

A number of other equities analysts also recently weighed in on VSTM. Jefferies Group reaffirmed a “hold” rating and issued a $1.50 price target on shares of Verastem in a research note on Friday, August 5th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $3.00 price target on shares of Verastem in a research note on Tuesday, August 9th. Zacks Investment Research raised shares of Verastem from a “hold” rating to a “buy” rating and set a $1.50 price target on the stock in a research note on Thursday, August 11th. Finally, HC Wainwright set a $5.00 target price on shares of Verastem and gave the stock a “buy” rating in a research report on Tuesday, October 4th.

Shares of Verastem (NASDAQ:VSTM) opened at 1.25 on Friday. The company’s market capitalization is $46.24 million. Verastem has a one year low of $1.05 and a one year high of $2.43. The company has a 50-day moving average price of $1.32 and a 200 day moving average price of $1.37.

Verastem (NASDAQ:VSTM) last announced its quarterly earnings data on Monday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.24) by $0.03.

A number of institutional investors have recently bought and sold shares of the company. AWM Investment Company Inc. increased its position in Verastem by 40.0% in the second quarter. AWM Investment Company Inc. now owns 1,400,000 shares of the biopharmaceutical company’s stock valued at $1,820,000 after buying an additional 400,000 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in Verastem during the first quarter worth about $585,000. Emerald Acquisition Ltd. purchased a new stake in Verastem during the second quarter worth about $179,000. Granite Point Capital Management L.P. purchased a new stake in Verastem during the second quarter worth about $179,000. Finally, GSA Capital Partners LLP purchased a new stake in Verastem during the second quarter worth about $179,000.

Verastem Company Profile

Verastem, Inc is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584.

5 Day Chart for NASDAQ:VSTM

Receive News & Stock Ratings for Verastem Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem Inc and related stocks with our FREE daily email newsletter.